Good morning, everyone, and how are you today? We are doing just fine, thank you, especially as a shiny sun and deliciously cool breeze are enveloping the unusually quiet Pharmalot campus. One short person is off to work, the other is sleeping in, and our official mascot is snoozing somewhere on the premises. We hear the heavy breathing. As for us, we are brewing more cups of stimulation — butter pecan is the choice today, for those keeping track — and we invite you to join us. Now, though, time to get cracking. Here are a few items of interest to help you on your journey. And may it be a good one. Talk soon. …

The deal between Pfizer (PFE) and Mylan (MYL) may provide a big payday for Mylan chief executive Heather Bresch, the Pittsburgh Post-Gazette notes. Under terms of her contract described in Securities and Exchange Commission filings, if Bresch meets the terms, she is in line to receive severance equal to three times her $1.3 million base salary and the highest bonus she had been paid, which amounts to $18.6 million in cash. And she will pick up vested benefits, estimated at $19 million at the end of last year, for a total of $37.5 million.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy